Health Care Equipment & Services

Lucid Diagnostics insider CMO adds 650k restricted shares, signaling leadership confidence in its esophageal‑cancer diagnostics platform and potential upside.

Elevance Health insider activity shows board confidence: Aziz Kabeer’s share purchase, high option volume, and Medicare/Medicaid expansion signal long‑term value, yet investors should watch upcoming option expirations for potential dilution.

Sonida Senior Living insider sale: CEO and CFO sell, SVP Tabitha divests 402 shares—small move amid big capital re‑org plans for APAC expansion.

Insightful look at Sophia Genetics’ insider sales: understand why CEO Camblong Jurgi and other execs are liquidating shares, what it means for investors, and how the company’s growth trajectory remains solid.

Omada Health insider sale: CEO Wei‑Li Shao sells 2,829 shares at $12.71, reflecting liquidity management and short‑term confidence rather than a warning of decline.

CEO and senior officers’ modest 10(b)(5)(1) sales at Sophia Genetics reveal routine tax‑liquidity planning, not a price‑dump, keeping shares steady amid growth buzz.

CEO Feldschuh’s fresh 1,000‑share buy at $9.07 shows confidence in Daxor’s blood‑volume tech launch and bullish stock outlook amid rising investor interest.

Insider sales at Hologic’s merger reveal confidence in the $76 cash payout and hint at a strategic shift under Hopper Parent Inc., affecting future earnings and shareholder value.

Hologic insider sales post‑merger: Stewart Stacey sold 8,358 shares and options after the Hopper deal, signalling a strategic exit, not a downturn. Explore what this means for Hologic’s future and investors.

Insider sales at Hologic spike as the company heads to a Blackstone‑TPG takeover—what the timing means for investors and future stock value.